Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

​

On June 4, 2026, Aclaris Therapeutics, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). The stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2026 (the "Proxy Statement"). Of the 139,663,680 shares outstanding as of the record date, 112,499,671 shares, or approximately 80.55%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: The stockholders elected two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

​ ​ ​ ​ ​ ​					​	​
Name	​ ​ ​	Votes For		Votes Withheld	​	Broker Non-Votes
Anand Mehra, M.D.		83,063,569	​	10,075,624	​	19,360,478
Maxine Gowen, Ph.D.		84,209,108		8,930,085	​	19,360,478

​

Proposal No. 2: The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows:

​

​ ​ ​ ​ ​ ​						​	​
Votes For			Votes Against		Abstained	​	Broker Non-Votes
83,370,124			9,734,691	​	34,378	​	19,360,478

​

​

Proposal No. 3: The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:

Votes For		Votes Against		Abstained
112,322,811		159,714	​	17,146

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​